ReviewNature reviews. Urology2010
Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors.
Review in Nature reviews. Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis.EBioMedicine · 2018Pooled it
- The role of microRNA in castration-resistant prostate cancer.Urologic oncology · 2014Pooled it
- MicroRNA novel-miR-90-5p modulates larval molt development in Ostrinia furnacalis (Guenée) by targeting OfCYP18A1.Insect science · 2026Article
- Comparison of microRNA-21 expression in bladder cancer tumor with normal-appearing adjacent tissue and healthy controls.International urology and nephrology · 2025Article
- Urine biomarkers in bladder cancer - current status and future perspectives.Nature reviews. Urology · 2023Review
- A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.Journal of translational medicine · 2023Article
- MicroRNAs as Potential Liquid Biopsy Biomarker for Patients with Castration-Resistant Prostate Cancer.Research and reports in urology · 2022Article
- Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.Cancers · 2021Article
- Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests.International journal of molecular sciences · 2021Review
- Review
- Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts.JNCI cancer spectrum · 2020Review
- The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms.Diagnostics (Basel, Switzerland) · 2020Article
- Radiogenomics in Clear Cell Renal Cell Carcinoma: Correlations Between Advanced CT Imaging (Texture Analysis) and MicroRNAs Expression.Technology in cancer research & treatment · 2019Article
- Article
- Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics.BMC urology · 2017Article
- LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.Cell death and differentiation · 2017Article
- Current Concepts of Epigenetics in Testicular Cancer.Indian journal of surgical oncology · 2017Review
- MicroRNAs in biofluids are novel tools for bladder cancer screening.Oncotarget · 2017Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that have an important role in the regulation of carcinogenic pathways. The observations that miRNAs are differentially expressed in tumor versus corresponding normal tissue, and that they regulate important breakpoints during carcinogenesis, are of interest for urologic oncologists. As biomarkers, they might be helpful tools for diagnostic, prognostic and monitoring purposes. Furthermore, miRNAs might be potential targets for novel therapeutic strategies, especially in patients with tumor subtypes that do not respond to currently available therapies. In this Review, we will focus on the current proceedings of miRNA research in urologic tumors. In the past decade, the number of published articles related to miRNAs in urologic oncology has increased, highlighting the ongoing importance of miRNAs in this field. Current studies support the hypothesis that miRNA will gain influence in clinical practice. Here, therefore, we illustrate the current knowledge of miRNA function in urologic tumors and draw the attention of urologists to the future opportunities and challenges of this research field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.